Niacin and Selenium Combination Therapy in Patients With Septic Shock (NISE-1)

November 10, 2026 updated by: Woon Yong Kwon, Seoul National University Hospital

Combination Therapy of Niacin and Selenium in Patients With Septic Shock (Phase IIa Single Center Double-blind Randomized Controlled Trial)

This study will test whether adding niacin, a form of vitamin B3, and selenium, a mineral, to standard treatment improves organ function in adults with septic shock. It will also assess the safety of this combination.

The study plans to enroll 148 patients aged 19 years or older in the emergency intensive care unit at Seoul National University Hospital in South Korea. Participants will be assigned by chance to one of two groups, with an equal chance of receiving either niacin plus selenium or placebo infusions. The placebo infusions use saline and glucose (sugar) solutions and do not contain the study drugs. All participants will receive standard treatment for septic shock.

Study treatments will be given through a vein twice a day during the first week of hospitalization. Participants and the researchers assessing outcomes will not know which treatment each participant receives. The study pharmacist and a designated team that prepares and gives the infusions will know the treatment assignments.

The main comparison will be organ function on the seventh day of hospitalization, measured using the Sequential Organ Failure Assessment (SOFA) score. This score measures how well several organs are working. Researchers will also compare survival at 28 and 90 days, time spent in intensive care, and time on a breathing machine. Blood samples will be collected at enrollment, approximately 72 hours later, and on study day 7 to measure niacin and selenium levels and biomarkers related to antioxidant activity and oxidative stress. Possible side effects will be monitored through daily assessments and blood tests.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Oxidative stress and dysregulated inflammatory responses contribute to tissue injury and organ dysfunction in septic shock. The rationale for combining niacin and selenium is to enhance intracellular antioxidant defenses through complementary effects on the glutathione redox cycle.

Preclinical experiments showed that niacin increased glutathione reductase activity and selenium increased glutathione peroxidase activity. Combined treatment reduced hydrogen peroxide levels, attenuated lung injury, and improved survival in rat models of sepsis. These findings provide a biological basis for evaluating the combination as an adjunctive treatment in patients with septic shock.

The study hypothesis is that combined niacin and selenium treatment during the acute phase of septic shock may reduce oxidative and inflammatory injury and thereby limit organ dysfunction. This study is intended to provide preliminary clinical evidence on efficacy and safety and to inform the planning of a subsequent multicenter trial.

Study Type

Interventional

Enrollment (Estimated)

148

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Hayoung Kim, MD, PhD
  • Phone Number: 82-2-2072-3257
  • Email: mogu13@naver.com

Study Locations

      • Seoul, South Korea, 03080
        • Seoul National University Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • WOON YONG KWON, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 19 years or older, irrespective of sex or race.
  • Admission to the emergency intensive care unit at Seoul National University Hospital with septic shock, defined by all of the following:

Infection-related organ dysfunction with a Sequential Organ Failure Assessment (SOFA) score of 2 or greater.

Sepsis-induced hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher.

A blood lactate concentration of 2 mmol/L or higher despite administration of 30 mL/kg of intravenous crystalloid fluid. If this volume cannot be administered because of pulmonary edema, heart failure, chronic renal failure, or other clinical limitations, the maximum clinically tolerated volume of crystalloid fluid must have been administered.

Written informed consent provided by the participant or an authorized representative.

Informed consent and randomization completed within 24 hours after the diagnosis of septic shock.

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Age younger than 19 years.
  • Cardiac arrest requiring cardiopulmonary resuscitation before admission to the emergency intensive care unit.
  • Expected death within 72 hours because of the severity of illness.
  • Patients for whom aggressive treatment is not being provided in accordance with an advance directive.
  • Known pre-existing liver failure with a Child-Pugh score of 10 or greater.
  • Lack of informed consent from the participant or an authorized representative.
  • Any other condition or circumstance that, in the investigator's judgment, makes participation in the trial inappropriate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Niacin plus Selenium

Participants receive intravenous niacin plus selenium every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.

Niacin (nicotinic acid) is supplied by Christmas Co., Ltd. (South Korea) as V-Tree Inj., a solution for injection containing 50 mg of niacin per 1 mL ampoule. A dose of 100 mg will be diluted with 0.9% sodium chloride solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

Selenium is supplied as selenase T pro injectione (biosyn Arzneimittel GmbH, Germany), a solution for injection containing 500 micrograms of selenium as sodium selenite pentahydrate per 10 mL vial (50 micrograms/mL). A dose of 5 micrograms/kg of selenium will be diluted with 5% dextrose solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

Placebo Comparator: Placebo

Participants receive intravenous placebo infusions of 0.9% sodium chloride and 5% dextrose every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.

Participants receive 50 mL of 0.9% sodium chloride solution as the placebo for niacin. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

Participants receive 50 mL of 5% dextrose solution as the placebo for selenium. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sequential Organ Failure Assessment (SOFA) Score on Hospital Day 7
Time Frame: Hospital day 7

Total Sequential Organ Failure Assessment (SOFA) score assessed on hospital day 7. The SOFA score evaluates six organ systems: respiratory, coagulation, liver, cardiovascular, central nervous system, and renal. Each component is scored from 0 to 4, giving a total score of 0 to 24; higher scores indicate more severe organ dysfunction. The day-7 score will be compared between groups using analysis of covariance, with adjustment for the SOFA score at admission.

Hospital day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
28-Day Survival
Time Frame: From hospital admission (hospital day 0) through day 28

Survival will be assessed from hospital admission, defined as hospital day 0, through day 28. The probability of survival at day 28 will be estimated using the Kaplan-Meier method.

From hospital admission (hospital day 0) through day 28
90-Day Survival
Time Frame: From hospital admission (hospital day 0) through day 90

Survival will be assessed from hospital admission, defined as hospital day 0, through day 90. The probability of survival at day 90 will be estimated using the Kaplan-Meier method.

From hospital admission (hospital day 0) through day 90
Length of Intensive Care Unit Stay
Time Frame: From hospital admission (hospital day 0) through hospital day 90

Length of stay in the intensive care unit, measured in days, during follow-up through hospital day 90.

From hospital admission (hospital day 0) through hospital day 90
Duration of Mechanical Ventilation
Time Frame: From hospital admission (hospital day 0) through hospital day 90

Duration of mechanical ventilation, measured in days, during follow-up through hospital day 90.

From hospital admission (hospital day 0) through hospital day 90

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pharmacologic, Antioxidant, and Mechanistic Biomarkers
Time Frame: At enrollment, 72 hours (±6 hours), and day 7

Blood samples will be analyzed to assess the biological effects of niacin and selenium treatment, including circulating niacin and selenium levels and biomarkers related to antioxidant activity, redox balance, and oxidative stress. Planned analyses include glutathione reductase activity, glutathione peroxidase activity, and hydrogen peroxide levels.

At enrollment, 72 hours (±6 hours), and day 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: WOON YONG KWON, MD, PhD, Seoul National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

April 30, 2028

Study Completion (Estimated)

July 31, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SNUH-NISE-2026
  • 2509-096-1679 (Other Identifier: Seoul National University Hospital Institutional Review Board)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data that underlie the results reported in the primary publication may be shared with qualified researchers upon reasonable request, subject to review and approval by the principal investigator and applicable institutional and ethical requirements. Data will be shared only in a manner that protects participant confidentiality and privacy.

IPD Sharing Time Frame

De-identified individual participant data and supporting information will be available beginning 6 months after publication of the primary study results and for 3 years thereafter.

IPD Sharing Access Criteria

De-identified individual participant data that underlie the results reported in the primary publication, together with the study protocol and statistical analysis plan, may be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the principal investigator and must comply with applicable institutional and ethical requirements. Approved data will be provided through a secure data-sharing method after execution of any required data use agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.